Literature DB >> 35027758

HLA-independent T cell receptors for targeting tumors with low antigen density.

Jorge Mansilla-Soto1,2, Justin Eyquem3,4,5, Sascha Haubner3,4, Mohamad Hamieh3,4, Judith Feucht3,4,6, Noémie Paillon7, Andrés Ernesto Zucchetti7, Zhuoning Li8, Maria Sjöstrand3,4, Pieter L Lindenbergh3,4, Michelle Saetersmoen3,4,9, Anton Dobrin3,4, Mathieu Maurin7, Archana Iyer3,4, Andreina Garcia Angus3,4, Matthew M Miele8, Zeguo Zhao3,4, Theodoros Giavridis3,4,10, Sjoukje J C van der Stegen3,4, Fella Tamzalit4, Isabelle Rivière3,11,12, Morgan Huse4, Ronald C Hendrickson8,12, Claire Hivroz7, Michel Sadelain13,14.   

Abstract

Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor-CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR. We demonstrate that these HLA-independent T cell receptors (HIT receptors) consistently afford high antigen sensitivity and mediate tumor recognition beyond what CD28-based CARs, the most sensitive design to date, can provide. We demonstrate that the functional persistence of HIT T cells can be augmented by constitutive coexpression of CD80 and 4-1BBL. Finally, we validate the increased antigen sensitivity afforded by HIT receptors in xenograft mouse models of B cell leukemia and acute myeloid leukemia, targeting CD19 and CD70, respectively. Overall, HIT receptors are well suited for targeting cell surface antigens of low abundance.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35027758      PMCID: PMC9469647          DOI: 10.1038/s41591-021-01621-1

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


  48 in total

1.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors:  John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

Review 2.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

3.  B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Authors:  Adam D Cohen; Alfred L Garfall; Edward A Stadtmauer; J Joseph Melenhorst; Simon F Lacey; Eric Lancaster; Dan T Vogl; Brendan M Weiss; Karen Dengel; Annemarie Nelson; Gabriela Plesa; Fang Chen; Megan M Davis; Wei-Ting Hwang; Regina M Young; Jennifer L Brogdon; Randi Isaacs; Iulian Pruteanu-Malinici; Don L Siegel; Bruce L Levine; Carl H June; Michael C Milone
Journal:  J Clin Invest       Date:  2019-03-21       Impact factor: 14.808

4.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

Review 5.  The pharmacology of second-generation chimeric antigen receptors.

Authors:  Sjoukje J C van der Stegen; Mohamad Hamieh; Michel Sadelain
Journal:  Nat Rev Drug Discov       Date:  2015-07       Impact factor: 84.694

Review 6.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

Review 7.  Therapeutic T cell engineering.

Authors:  Michel Sadelain; Isabelle Rivière; Stanley Riddell
Journal:  Nature       Date:  2017-05-24       Impact factor: 49.962

Review 8.  Chimeric antigen receptor T-cell therapies for lymphoma.

Authors:  Jennifer N Brudno; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

Review 9.  Targeting tumours with genetically enhanced T lymphocytes.

Authors:  Michel Sadelain; Isabelle Rivière; Renier Brentjens
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

10.  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Authors:  Terry J Fry; Nirali N Shah; Rimas J Orentas; Maryalice Stetler-Stevenson; Constance M Yuan; Sneha Ramakrishna; Pamela Wolters; Staci Martin; Cindy Delbrook; Bonnie Yates; Haneen Shalabi; Thomas J Fountaine; Jack F Shern; Robbie G Majzner; David F Stroncek; Marianna Sabatino; Yang Feng; Dimiter S Dimitrov; Ling Zhang; Sang Nguyen; Haiying Qin; Boro Dropulic; Daniel W Lee; Crystal L Mackall
Journal:  Nat Med       Date:  2017-11-20       Impact factor: 53.440

View more
  7 in total

1.  Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage.

Authors:  Alessio David Nahmad; Eli Reuveni; Ella Goldschmidt; Tamar Tenne; Meytal Liberman; Miriam Horovitz-Fried; Rami Khosravi; Hila Kobo; Eyal Reinstein; Asaf Madi; Uri Ben-David; Adi Barzel
Journal:  Nat Biotechnol       Date:  2022-06-30       Impact factor: 54.908

2.  Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.

Authors:  Sjoukje J C van der Stegen; Pieter L Lindenbergh; Roseanna M Petrovic; Hongyao Xie; Mame P Diop; Vera Alexeeva; Yuzhe Shi; Jorge Mansilla-Soto; Mohamad Hamieh; Justin Eyquem; Annalisa Cabriolu; Xiuyan Wang; Ramzey Abujarour; Tom Lee; Raedun Clarke; Bahram Valamehr; Maria Themeli; Isabelle Riviere; Michel Sadelain
Journal:  Nat Biomed Eng       Date:  2022-08-08       Impact factor: 29.234

Review 3.  Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-06-26

4.  High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.

Authors:  Brian R Shy; Vivasvan S Vykunta; Alvin Ha; Alexis Talbot; Theodore L Roth; David N Nguyen; Wolfgang G Pfeifer; Yan Yi Chen; Franziska Blaeschke; Eric Shifrut; Shane Vedova; Murad R Mamedov; Jing-Yi Jing Chung; Hong Li; Ruby Yu; David Wu; Jeffrey Wolf; Thomas G Martin; Carlos E Castro; Lumeng Ye; Jonathan H Esensten; Justin Eyquem; Alexander Marson
Journal:  Nat Biotechnol       Date:  2022-08-25       Impact factor: 68.164

Review 5.  Clinical implications of T cell exhaustion for cancer immunotherapy.

Authors:  Andrew Chow; Karlo Perica; Christopher A Klebanoff; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2022-10-10       Impact factor: 65.011

6.  High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA.

Authors:  Soyoung A Oh; Kate Senger; Shravan Madireddi; Ilseyar Akhmetzyanova; Isabel E Ishizuka; Somayeh Tarighat; Jerry H Lo; David Shaw; Benjamin Haley; Sascha Rutz
Journal:  J Exp Med       Date:  2022-04-22       Impact factor: 17.579

Review 7.  New insights into CAR T cell-mediated killing of tumor cells.

Authors:  David Espie; Emmanuel Donnadieu
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.